Completed PHASE2 INTERVENTIONAL 2-arm NCT03990051

Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.

Treatment Safety and Efficacy Using Pro-ocular™ 1% for Chronic Ocular Graft-versus-host Disease (GvHD) Following Allogeneic Hematopoietic Stem Cell Transplantation.

Sponsor: Glia, LLC

Conditions Chronic Ocular Graft-versus-host Disease

Interventions Placebo topical gel Pro-ocular™ topical gel

Updated 7 times since 2019 Last updated: Apr 16, 2025 Started: Oct 17, 2019 Primary completion: Oct 31, 2021 Completion: Nov 19, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Chronic Ocular Graft-versus-host Disease and is currently completed. Glia, LLC leads this study, which shows 7 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Jun 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Jun 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2023 — Jul 2024 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Apr 2021 — Apr 2023 [monthly]

Active Not Recruiting PHASE2

Status: Enrolling By Invitation → Active Not Recruiting

▶ Show 2 earlier versions

Jan 2021 — Apr 2021 [monthly]

Enrolling By Invitation PHASE2
Jul 2019 — Jan 2021 [monthly]

Enrolling By Invitation PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Glia, LLC
ORA, Inc.

Data source: Glia, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States